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ABSTRACT

The ret proto-oncogene codes for a receptor tyrosine kinase involved in the pathogenesis of nu
merous developmental defects, particularly those in neural crest-derived structures leading to the
regulation of cell proliferation, migration, differentiation and survival during embryogenesis.
Constitutive activation or inactivation of the RET receptor results in the cancer syndrome Multi
ple Endocrine Neoplasia or Hirschsprung's disease, respectively. The importance of RET in these
disease states has been well established. However, while many proteins associated with the RET
signaling pathway have been identified, the transcriptional changes induced by the wild type re
ceptor, particularly with respect to these signaling proteins in neuroblastoma cells, is less clear. In
order to better understand the transcriptional changes that occur in response to RET activation,
SK-N-SH neuroblastoma cells were treated with 100 ng/ml GDNF and the RNA isolated. Focus
ing on the changes in transcription of specific genes that occur in response to the activation of
RET, including Etv4, Spryl and Shp2, primers for these genes were designed and the genes char
acterized using standard RT-PCR and then further analyzed using real-time PGR. Some of these
genes promote and control branching in kidney morphology while others, when mutated, are as
sociated with several human diseases. Analyzing the expression levels of each gene in response to
the activation of RET will aid in elucidating RET-mediated mechanisms that contribute to these
diseases and understanding the role of RET on downstream signaling and cellular function.
These findings show quantitatively minimal effect on Spryl, Shp2 and Etv4 expression in re
sponse to 4-hour GDNF treatment in neuroblastoma cells by real-time PGR. Because the fold
changes observed were not remarkable, the data suggests that expression regulation of these pro
teins may not be dependent on RET activation. Future studies include analyzing transcriptional
changes of these signaling proteins in response to RET activation with longer GDNF treatments
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or by combination of different ligand stimulation to help further elucidate the possible role of
RET on these signaling proteins.
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INTRODUCTION
STRUCTURE of RECEPTOR TYROSINE KINASES
Cells have the ability to sense cues in their environment, process these cues and respond accord
ingly. Such processes are mediated through a diverse group of cell surface receptors, including a
group called receptor tyrosine kinases (RTKs). RTKs represent a family of proteins present in all
metazoans that have been conserved over evolutionary time because of their ability to contribute
to the fitness of the organism in which they are expressed. The conservation of RTKs in mam
mals suggest that each is responsible for cellular communication to regulate different cellular pro
cesses including proliferation, differentiation, migration, survival, protein synthesis, metabolism
and other cellular outcomes. The study of orthologs of human proteins in the nematode worm
Caenorhabditis elegans elude to their respective functions in both species. The structure of RTKs is
highly conserved from the C. elegans, and is described as an extracellular domain containing a lig
and-binding site, a single hydrophobic transmembrane domain and an intracellular catalytic do
main with protein tyrosine kinase activity. The kinase gene in C. elegans describes the mechanism
by which RTKs have driven their evolution by gene duplication and thus, the mechanisms that
influence evolution (Popovici et ah, 1999).

Gene duplication highlights one of the main reasons for the extensive RTKs identified in the hu
man genome (Yarden and Wheeler, 2015). In gene duplication, two identical copies exist for a
particular function that was originally fulfilled by one copy. Consequently, only one copy is con
sidered functional while the other is considered dispensable. The dispensable copy can either ac
quire mutations that may impair its function, or evolve an acquired function. The acquired func
tion will remain as a paralogue of the original gene and may be expressed in different cell types,
may be activated by different ligands or become involved in related signaling pathways. Other
wise, the dispensable copy and the functional copy can share the function of the ancestral gene.
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The gene sequence similarities across these three possible outcomes give rise to the RTK gene
families.

Takahashi et. al., first identified the c-ret protooncogene as part of an oncogenic fusion protein
resulting from a translocation assay in vitro (Takahashi et al., 1985). The gene, named rearranged
during transfection (ret) was found to encode a structurally unique transmembrane receptor tyro
sine kinase. Characterization of the gene, on human chromosome lOql 1.2, revealed the primary
structure of the RET protein (figure 1): an extracellular region consisting of four cadherin-like
domains including a calcium binding site, the cysteine-rich extracellular domain that mediates co
receptor and ligand binding, a hydrophobic transmembrane domain and the intracellular catalyt
ic tyrosine kinase domain with two flanking regulatory regions, the junxtamembrane and C-tail
with tyrosine residue phosphorylation sites (Takahashi et al. 1988; Anders et al. 2001). Alternative
splicing of the protein gives rise to two functionally distinct isoforms of RET that differ in their
respective C-terminus tail, named RET 9 and RET 51 (Tahira et al., 1990).

The RET proto-oncogene represent a receptor tyrosine kinase. There are 90 tyrosine kinase
genes in the human genome, of which 58 encode receptor tyrosine kinases (Robinson et al., 2000).
The catalytic tyrosine kinase domain is the most conserved part of RET with 90 percent sequence
similarity to vertebrate lineages and, to a lesser extent, the extracellular domain with 40 percent
sequence similarity with RET vertebrate species (Hahn and Bishop, 2001). The cysteine rich do
main (CRD) found within the extracellular domain of RET represents a homologous structural
motif used to identify RET in lower organisms (Takahashi, 2001). Fourteen of the twenty-eight
cysteines are conserved between human, zebrafish and Drosophila species (Hahn and Bishop,
2001). Studies have traced the evolutionary conservation of the RET protein sequence and its
expression in development across different organisms. Expression of endogenous RET has been
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described in cells originating from the neural ectoderm termed the neural crest. In D. melanogaster,
the fruit fly, minimal amounts of RET are found in embryonic, larval and pupil stages (Sugaya et
al., 1994). RET is also expressed in the late embryo in subpopulations of the central nervous sys
tem and peripheral nervous system (Sugaya et al., 1994). In B. ranio, the zebrafish, RET is detect
ed in the nervous system and excretory system. In the nervous system, RET is found in primary
and motor neurons as well as neural crest cells and ganglion cells. In the excretory system, RET
is present in the developing functional part of the kidney, termed the nephron duct (MarcosGutierrez etal., 1997).

The two isoforms of the RET protein are expressed in higher organisms such as the chicken,
mouse and human. The catalytic domain of the chicken is 91 percent similar to the human RET
protein while the extracellular domain is 68 percent similar to human RET (Marcos-Gutierrez et
al., 1997). The cysteine residues present in the extracellular domain of the chicken RET protein
suggest the residues represent a conserved structure. During chicken embryogenesis, RET is ex
pressed in sites of the nervous system and excretory system (Schuchardt et al., 1995). In addition,
RET is found in the development of the ventral roots of the spinal cord, the mesenchymal cells
and adult testes (Schuchardt et al., 1995), eluding to the role of RET in early development. Fur
ther, the extracellular and catalytic domains are similar in structure in both the mouse and human
RET proteins. The nucleotide sequence of the mouse RET protein is 83 percent similar to the
human RET protein (Iwamoto et al., 1993). The similarities in RET expression between higher
and lower organisms suggest the function of RET has been conserved during evolutionary time.
The extent of homology between vertebrate and invertebrate species suggests RET may function
similarly in terms of downstream signaling patterns across the organisms (Abrescia et al., 2005).
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MODES of RECEPTOR ACTIVATION
Signaling pathways begin with a ligand binding to a receptor. While there are many receptors on
the surface of a cell, the receptor will only bind to a specific ligand or set of ligands. The signal
ing molecule, which can be a functional group, growth factor, neurotransmitter, antigen or a hor
mone behaves as a ligand to change the properties of the receptor. Most signaling molecules are
water-soluble and cannot bypass the cell membrane without binding to a cell surface receptor.
After a ligand binds to a cell surface receptor, other processes, such as internalization, degradation
or recycling can determine which signaling pathway is activated or deactivated as well as the du
ration of the signal (Ullrich and Schlessinger, 1990). Ligand binding is necessary to stabilize the
receptor regardless of whether the receptor is monomeric or oligomeric in its inactive state, but
activation may also occur in the absence of the ligand. Most commonly, growth factor binding
activates the receptor by inducing dimerization (Ullrich and Schlessinger, 1990).

RET is the signaling receptor for the glial-cell derived neurotrophic factor (GDNF) family of sol
uble, covalent, dimeric ligands (Trupp et al., 1996; Treanor et al., 1996; Durbec et al., 1996).
GDNF was initially identified as a trophic factor for dopaminergic neurons (Lin et al., 1993) and
later found involved in survival of sensory and motor neurons of the enteric nervous system
(Baloh et al., 2000). The four proteins, GDNF, Neurturin (NTN), Persephin (PSP) and Artemin
(ART) have been renamed GDNF family ligands (GFLs) (Baloh et al., 2000). This family of pro
teins form a subdivision of the transforming growth factor (3 (TGF-J3) superfamily, being the only
members of that family to signal via a RTK (Mason, Ivor, 2000). NTN, PSP and ART share simi
lar characteristic to that of GDNF. However, GFLs do not bind to the extracellular domain of
RET directly. They bind indirectly by first forming a complex with one of the four glycosly-phosphatidylinositol (GPI) anchored GFRa co-receptors (G FR al-4). The ligand binds to the co-receptor based on high affinity to form the following complexes: GDNF —» G FR al; NTN —*
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GFRa2; ART —> GFRa3; and PSP —* GFRa4 (Mason, Ivor, 2000). Although each GFL ligand
exhibits a preference for a specific GFRa co-receptor, different complexes may be formed depen
dent on the receptor and co-receptor localization. Other functional complexes formed based on
low affinity: GDNF —» GFRa2; NTN —» G FR al; ART —> G F R al may also activate RET
(Trupp et ah, 1996; Mason, Ivor, 2000).

The receptor’s signal transduction is dependent on the assistance of lipid rafts on the plasma
membrane. The complex formation between the ligand, co-receptor and receptor is mediated by
the scaffolding properties of lipid rafts on the cell membrane. Jing et al., 1996 described the RET
receptor complex formation with respect to the lipid rafts in two different ways. First, the dimeric
GFL ligand ligates the two monomers of the GFRa co-receptor, which are commonly located in
the lipid raft. Alternatively, the GFRa co-receptor is cleaved from the plasma membrane to pro
duce a soluble form that associates with the dimeric GFL ligand. The complex then recruits RET
to the lipid raft and promotes its homodimerization, which in turn, leads to activation. Dimeriza
tion of RET can stimulate autophosphorylation of specific tyrosine residues on the intracellular
catalytic domain.

The activation mechanism by which ligand-induced dimerization leads to kinase activation differs
for the particular RTK. The activation loop of the kinase domain in RTKs adopts a conforma
tional change that mediates phosphotransferase catalytic activity. Protein kinases catalyze the
transfer of the gamma phosphate group from adenosine triphosphate to a tyrosine residue on a
substrate protein. Protein phosphatases transfer the phosphate group from a phosphoprotein to a
water molecule. Such enzymes are termed phosphotransferases and catalyze opposing reactions
to mediate kinase domain activity. Protein phosphorylation and dephosphorylation are a signal
ing motif that defines RTK activation. The crystal structures of the activated kinase domains of
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RTKs are very similar because all kinase domains include an N and C-terminal lobe. The crystal
structures of the inactivated kinase domains differ across RTKs, suggesting they may regulate in
different ways (Huse and Kuriyan, 2002). In unstimulated conditions, the catalytic domains of
most kinases are monomeric and auto-inhibited in cis by the C-lobe activation loop that keeps the
kinase pocket closed. In stimulated conditions, inhibition is relived and the receptor is activated
by the binding of specific ligands that stimulate the receptor’s protein tyrosine kinase activity (Ull
rich and Schlessinger, 1990).

The RET intracellular catalytic tyrosine kinase domain is predicted to adopt the classical fold con
formation involving the N-terminal lobe and C-terminal lobe connected by the linker region
(Knowles et ah, 2006). Instead of a cis conformation, RET adopts a trans conformation that
blocks the substrate binding site of each monomer within the inactive dimer (Knowles et al.,
2006). Ligand growth factor stimulation brings the two intracellular parts of the RET homo
dimer in proximity of one another, such that, the auto-inhibitory constraints are relieved, thereby
favoring the formation of an active dimer that allows for catalytic activity of the kinase domain.
The catalytic activity of the kinase domain that leads to different signaling pathways is described
by the phosphorylation of specific tyrosine residues. 7rarcj-autophosphorylation can be divided
into two parts each with specific catalytic properties. The first wave of phosphorylation serves to
enhance the catalytic activity of the kinase once the receptor binds to its ligand. The second wave
creates the phophotyrosine binding sites that recruit cytoplasmic signaling molecules that include
binding domains. The resulting phosphotyrosines serve as docking sites for other protein-protein
interactions involved in the RTK-mediated signaling pathway.
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RET in DISEASE and DEVELOPMENT
RET plays an essential role in development of the nervous and enteric systems, and in signaling
during development of the mammalian kidney. The neural crest cells originate in the dorsal most
part of the neural tube and migrate extensively to generate differentiated cell types including sub
populations of the enteric, sensory and sympathetic nervous systems (Pachnis et ah, 1993). The
different substitutions and rearrangements in the ret gene underlie various human diseases includ
ing four different human cancers: papillary thyroid carcinoma (PTC), familial medullary thyroid
carcinoma (MTC) and multiple endocrine neoplasia types 2A and 2B (MEN 2A and MEN 2B)
(Grieco et al., 1990; Donis-Keller, Helen, et al. 1993; Mulligan et ah, 1993; Hofstra et ah, 1994).
A chromosomal rearrangement of RET leads to oncogenic properties of the protein present in
human papillary thyroid carcinomas (PTC) (Grieco et al., 1990).

MTC is a cancer syndrome that affects tissues derived from the neural ectoderm, specifically
glands of the endocrine system. MTCs are rare tumors of the neural crest that arise from calci
tonin secretion by a subset of cells in the thyroid glands named parafollicular C cells. MTC is
classified into three types: familial MTC, MEN 2A and MEN 2B, and are characterized by the
types of tumors and the age of onset of the disease (Donis-Keller, Helen, et al. 1993; Santoro et
al., 1995). Mutations to RET account for a quarter of inherited MTCs that are either sporadic or
familial. Sporadic MTC arises from somatic mutations of the RET protein and generally
presents as a tumor confined to one thyroid lobe. Familial MTC results from germ-line mutations
of the RET protein and often present as bilateral tumors (Donis-Keller, Helen, et al. 1993; San
toro et al., 1995).

MEN2 is a hereditary cancer defined by defects to major glands of the endocrine system includ
ing the thyroid, parathyroid and adrenal glands. MEN 2A usually occurs during early adulthood
Page 16 of 85

and is characterized by MTC and tumors of the adrenal gland and neuroendocrine tissues named
phaeochromocytoma (Donis-Keller, Helen, et al. 1993; Mulligan et al., 1993). The MEN 2A
gene has been mapped to the DNA sequence on chromosome lOql 1.2 that also encompasses the
RET protein (Gardner et al., 1993J. Germ-line missense mutations of RET have been identified
in the majority of different MEN 2A families (Mulligan et al., 1993). The RET mutations associ
ated with MEN 2A are the cysteine residues 609, 611, 618, 620, 630 and 634. The majority of
mutations identified affect the same conserved cysteine residue 634 located on RET’s extracellular
domain suggesting RET as a target for the MEN 2A gene (Mulligan et al., 1993). In the absence
of the ligand, MEN 2A mutations leave an unpaired cysteine residue leading to the constitutive
dimerization of the RET monomers by intramolecular disulfide bonds, followed by constitutive
activation of the kinase domain (Santoro et al., 1995).

MEN 2B usually occurs in infancy or early childhood and is characterized by MTC and
pheochromocytoma, but also by mucosal neuromas and ganglioneuromas, which are tumors
composed of ganglion cells and nerve fibers of the gastrointestinal tract. MEN 2B has also been
associated with mutations of the RET proto-oncogene by a substitution of a threonine for a me
thionine in the tyrosine kinase catalytic domain of the protein (Hofstra et al., 1994). The muta
tion that accounts for most of MEN 2B is mapped to the residue 918 in the catalytic domain of
RET. This mutation induces conformation change of the kinase domain, resulting in activation
of RET protein without dimerization (Iwashita et al., 1996). The different point mutations in
MEN 2A, MEN 2B and FMTC that activate RET and disrupt development of the peripheral
nervous system are described as gain-of-function mutations.

The enteric nervous system (ENS) derives from neural crest cells, which migrate and differentiate
in the mesenchyme of the developing gut and subsequently become the gastrointestinal tract.
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Hirschsprung disease (HSCR) is a congenital, genetic disorder of the neural crest development
characterized by the absence of enteric parasympathetic neurons in the lower end of the gut.
While the RET mutations that underline the cancer syndromes are described as gain-of-function
mutations, HSCR is described by the inactivation of RET therefore are considered loss-of-function germ-line mutations (Schuchardt et al., 1994; Romeo et al., 1994). The disease is described as
a blockage of the large intestine due to poor muscle movement caused by lack of nerves in the
bowel and thus, results in an enlargement of the bowel and abdomen areas. Different types of
mutation to the RET protein result in the HSCR phenotype. Missense and frameshift mutations
found in the tyrosine kinase domain of RET show a decrease of kinase activity that is consistent
with the HSCR phenotype (Romeo et al., 1994). Mutations to the extracellular domain inhibit
RET’s cell surface expression caused by incorrect folding of the protein (Iwashita et al., 1996).
Consequently, RET-mediated signaling pathways are impaired. Thus, RET signals are essential
for the normal development of the enteric nervous system.

Besides RET’s role in the peripheral and enteric nervous system, it also plays a role in developing
mammalian kidney. As described by (Pietila et al., 2013), the development of the mammalian
kidney progresses through three stages, of which two are transient and the last remains as the
functional kidney. An important step in kidney development is the formation of the Wolffian duct
which can be defined as a simple epithelial tube from a group of cells that undergo mesenchymeto-epithelial transition in the mesoderm. A subset of cells adjacent to the group that give rise to
the Wolffian duct, gives rise to the non-functional primitive kidney, the pronephros. The
pronephros eventually degenerates and then the next kidney, the mesonephros begins to form.
The mesonephros consists of tubules that are connected peripherally to the Wolffian duct. The
mesonephros is also a transient structure because it later regresses to become part of the epi
didymis in males and the metanephros remains as the predominant kidney structure present in
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adult mammals. The metanephros appears as a tubular outgrowth of the Wolffian duct, known
as the ureteric bud (UB), that invaginated the metanephric mesenchyme in a process knows as UB
induction. While in the metanephric mesenchyme, the UB folds into a T-shaped structure with
two tips and a stalk and each subsequent tip continues to grow in a process termed branching
morphogenesis. Branching morphogenesis is led by interactive signaling between the UB epithe
lium and metanephric mesenchyme to become the collecting system of the kidney. Formation of
the kidney is completed before birth in humans, but continues after birth in mice.

Gene-targeting studies revealed the G D N F /G F R al/R E T signaling complex is physiologically
essential in different stages of kidney development. In mice, the proliferating Wolffian duct is
filled with cells that express RET and G FR al. RET-GFRal-expressing cells undergo cellular
rearrangement prior to migrating to what will become the UB (Pachnis et al., 1993; Cacalano et
al., 1998). GFRal-GDNF-expressing cells are located in the mesenchyme of the urinary system
adjacent to the Wolffian duct (Hellmich et al, 1996; Cacalano et al., 1998). The UB outgrowth
from the Wolffian duct is induced by GDNF signals from the mesenchyme and GDNF is proposed
to control the growth of the UB tips during branching morphogenesis (Vega et al., 1996). The
proliferating UB has the greatest amount of RET-GFRal expression while the UB stalk harbors
the least RET-G FRal expression (Schuchardt et al., 1994; Cacalano et al., 1998). During
branching morphogenesis, the UB fold is led by the high concentration of RET-expressing cells at
the distal UB tips (Pachnis et al., 1993). At this stage in development, the expression of G FR al in
the UB is much greater than that of the mesenchyme (Keefe et al., 2013). The expression of
RET-GFRal becomes weaker in the UB stalk, the ureter bud epithelium and the Wolffian duct as
the common nephron duct (CND) forms (Hoshi et al., 2012).
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Mutations in RET are associated with congenital anomalies of the kidney and urinary tract
(CAKUT) and these mutations have been revealed in three different in vivo experimental ap
proaches in mice. In the first approach, aberrant expression of RET caused multi-cystic dysplastic kidneys where the renal cortex is replaced by cysts during fetal development leading to a non
functional kidney (Srinivas et ah, 1999). In the second approach, nonfunctional RET and the ab
sence of G F R al caused downregulation of Erk in the Ras-Erk/MAPK pathway which resulted
in unilateral or bilateral renal agenesis, or kidney hypoplasia due to failure of the ureteric bud to
evaginate from the Wolffian duct and branch properly (Jain et al., 2004). In the last approach,
both isoforms of RET, promoted branching morphogenesis to an extent, but mutations in the
tyrosine residues ,Y1062, Y1015 and Y981, resulted in renal defects for RET 9 and not for RET
51 (Jain et al., 2006). The absence of Y1062 in kidney development disrupted the Ras-Erk/
MAPK and PI3K/Akt pathways. The absence of Y1062 and Grb2 in RET 9 resulted in bilateral
renal agenesis, a phenotype similar to non-functional RET mutations in mice. However, the ab
sence of Y1062 in RET 51 did not affect kidney development. The absence of the Src and Grb2
adaptors on Y981 in RET 9 resulted in unilateral or bilateral kidney agenesis. Conversely, the
absence of Src on Y981 in RET 51 resulted in normal kidneys. Moreover, loss of Y1015 signal
ing in RET prevents association with the adaptor phospholipase C gamma (PLC-y). Lack of
PLC-)' recruitment resulted in renal dysplasia described by multiplexed kidneys, enlarged ureters
and failure of gonads to properly develop in male and females (Jain et al., 2006). RET 51 pro
vides redundancy and promotes normal kidney formation via Y1096 when there are mutations to
Y981 orY1062 (de Graaff etal., 2001; Jain et al., 2006).
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THE SIGNALING PATHWAYS ACTIVATED by RET
RTK signaling is described as an interconnected network because of the many phosphorylation
sites present in the intracellular domain of RTKs and the multiple signaling proteins that may be
recruited at those individual phosphorylation sites. The signaling molecules may be recruited to
the phosphotyrosines in the receptor via receptor-proximal interactions such as Src homology 2
(SH2) and phosphotyrosine binding (PTB) binding domains (Schlessinger and Lemmon, 2003).
There are approximately 100 SH2 domains that have been identified in the human genome and
these domains mediate phosphorylation dependent protein-protein interactions. The signaling
molecules are adaptor proteins that contain these binding domains with a conserved bindingpocket that specifically attaches to the autophosphorylated tyrosine residues present on the recep
tor. The formation of a signaling complex occurs when a signaling protein containing an SH2 or
PTB domain binds directly or indirectly to a specific autophosphorylation site on the receptor.

Cells contain many proteins with SH2 and PTB domains that bind to phosphorylated tyrosine
residues including adaptor proteins, docking proteins, transcription factors and enzymes. Adaptor
proteins, such as growth factor receptor-bound protein 2 (Grb2), function as linkers that allow two
signaling proteins to bind together to form a signaling complex. Docking proteins, such as fibrob
last growth factor receptor substrate 2 (FRS2), insulin receptor substrate-1 (IRS1) and Grb2 asso
ciated binding proteins (GAB) provide receptors with additional tyrosine phosphorylation sites
and these interactions that are spatially and temporally removed function as binding sites for other
signaling proteins. (Schlessinger and Lemmon, 2003). Transcription factors may also bind to the
activated receptor and subsequently become translocated to the nucleus such as members of the
signal transducers and activators of transcription, (STAT) family. Enzymes such as (PLC-y), a
lipid phosphoinositide 3-kinase (PI3K) and a protein tyrosine phosphatase (SHP2) may also be
come become activated by binding to an activated receptor (Schlessinger and Lemmon 2010).
Page 21 of 85

RET regulates proliferation, differentiation, migration, survival, protein synthesis and other cellu
lar processes as a result of downstream signaling pathways, including Ras-Erk/MAPK, PLC-y,
PKC, PI3K/Akt, JAK/STAT, RAG1 andJNK (figure 2). The alternative splicing of the RET
protein adds complexity to the mechanism by which RET signals. The She proteins bind to both
of the RET isoforms. However, RET 9 will only associate with the SH2 binding domain whereas
RET 51 will only associate with the PTB binding domain of She adaptor proteins (Lorenzo et al.,
1997), suggesting differences in downstream signaling and regulation of cellular interactions.

Previous studies showed that 14 out of 18 tyrosine residues present in the intracellular cytoplasmic
region of RET can become autophosphorylated (Liu et al., 1996). The tyrosine residues Y905,
Y981, Y1015, Y1062, and Y1096 are important for further signaling propagation because each of
theses sites allow for multiple adaptor proteins including Src (Y981), Grb7/10 (Y905), PLC-y
(Y1015), Shc/IRSl or IRS2/DOKl,2,4,5 or DOK6 (Y1062) and Grb2/GABlor GAB2 (Y1096)
to associate with activated RET (Mason, Ivor, 2000). Amongst these, Y1015 and Y1062 have
been shown to be important for ligand-dependent and ligand-independent activation of RET
(Takahashi, 2001). Some of these adaptor proteins bind to the activated RET within the lipid
raft, while others prefer to bind to RET outside of the lipid raft. These binding sites have either
redundant or unique roles that are dependent on the tissue and cell type.

Apart from tyrosine autophosphorylation, other autophosphorylation sites contribute to RET ac
tivation. The serine residue, S696, is associated with protein kinase A (PKA) (Fukuda et al., 2002).
Mutations of this residue affect the ability of RET to activate the small GTPase Rac 1 and to in
duce formation of a flattened extension of a cell termed lamellipodia, that is important for cell
motility during cell migration (Fukuda et al., 2002). Alternatively, the S696 residue leads to the
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activation of the JN K pathway through binding of the PKA adaptor protein. In addition, activa
tion of PKA by forskolin, a chemical found in Plectranthus barbatus (Coleus forskohlii), was found to
block the recruitment of SHP2 to RET and negatively affect the ligand growth factor stimulation
(Perrinjaquet et ah, 2010). Moreover, mutations to S687 promote SHP2 binding to the receptor
and cancel the negative effects caused by forskolin.

The first tyrosine residue after the serine residue on the receptor that may become phosphorylated
is Y687. The tyrosine residue, Y687, is mapped to the junxtamembrane region of the RET in
tracellular domain (Perrinjaquet et ak, 2010). Upon growth factor stimulation, tyrosine-protein
phosphatase non-receptor type 11 (PTPN11), which is the gene that in humans encodes the SHP2
protein, binds to Y687, but is not linked to the transduction of a signaling pathway directly asso
ciated with RET. The following tyrosine residue that can become phosphorylated is Y786. Phos
phorylation of Y786 leads to the recruitment of the SHP2 and activation of the PI3K/Akt path
way. The PI3K/Akt pathway may be activated upon the recruitment of SHP2 to Y786 on the
activated receptor, but also with cooperative binding of Y1062. Both of the tyrosine residues
Y786 and Y 1062 are necessary for stable recruitment of SHP2 to the receptor to activate the
PI3K/Akt pathway (Perrinjaquet et al., 2010). SHP2 may promote survival and neurite out
growth in primary neurons through the binding of phosphotyrosine Y786 (Perrinjaquet et ak,
2010).

There are two tyrosine residues, Y900 and Y905, that map to the activation loop of the RET ty
rosine kinase domain and undergo autophosphorylation (Knowles et ak, 2006). The growth fac
tor receptor-bound protein 7 (Grb7) and protein growth factor receptor-bound protein (GrblO)
bind to the phosphotyrosine Y905 to induce signaling of the Ras-Erk/MAPK pathway. Following
Y905 is Y981 which can also become phosphorylated. The tyrosine residue, Y981, binds to the
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Src cytoplasmic tyrosine kinase and leads to the activation of the PI3K/Akt pathway (Encinas et
al., 2004). Most recently Y981 was found to associate with Rap 1GAP for RET binding and sup
press growth factor induced stimulation of Erk and neurite outgrowth (Jiao et ah, 2011). Finally,
the recruitment and phosphorylation of SHC adaptors to phosphotyrosine Y 1015 leads to the
binding of PLC-y and activation of the protein kinase C (PKC) (Borrello et ah, 1996).

The most well-characterized site on all of the RET protein’s isoforms is the tyrosine residue
Y1062. Upon ligand growth factor stimulation, two different protein complexes assemble on the
phosphorylated Y1062 via the Shcl transforming protein 1 (Asai et ah, 1996; Lorenzo et ah,
1997). One of the signaling complexes leads to the activation of the PI3K/Akt pathway through
the recruitment of the adaptor proteins Grb2 and Gabl or Gab2 (Besset et ah, 2000). The sec
ond signaling complex formation leads to the activation of the Ras-Erk/MAPK pathway through
the recruitment and phosphorylation of adaptor proteins Grb2 and/or Gab lor Gab2 (Besset et
al., 2000). Alternatively, FRS2 associates with Y1062 in competition with Shcl and leads to the
activation of the Ras-Erk/MAPK pathway through the recruitment of the adaptor proteins Grb2
and sons of sevenless (SOS) (Kurokawa et al., 2001). The JN K pathway is activated upon binding
of docking protein 1 (Dokl) and non-catalytic region of tyrosine kinase adaptor protein (Nek) to
Y1062 (Murakami et al., 2002). The adaptor proteins IRS1, IRS2 and docking proteins Dok2,
Dok4, Dok5 and Dok6 are also associated with Y1062 (Melillo et al., 2001; Grimm et al., 2001).
Tyrosine residue Y 1062 is important for RET function and has been shown to induce severe non
functional RET mutations in mice (Jijiwa et al., 2004). Growth retardation of the enteric nervous
system was observed when the tyrosine residue was replaced with phenyalanine (Jijiwa et al.,
2004). Mice with this mutation either lacked enteric neurons that line the inside of the intestinal
tract or developed enteric neurons with reduced ganglion cells, but the formation of a small kid
ney was achieved. Thus proving the signing via Y 1062 to be important for embryogenesis of the
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enteric nervous system and development or growth of the kidney (Jijiwa et al., 2004). Further, the
signaling complex formed via She 1 contributes to the survival of RET in neuroblastoma cells.
The survival properties of SK-N-MC cells were demonstrated in the competitive interaction of
Sch/ENIGMA and FRS2 to bind to Y1062 (Lundgren et ah, 2006). Thus suggesting cell survival
properties of RET are specific to cell type and occur in response to the competitive binding of
different Src adaptor to the tyrosine residue (Lundgren et ah, 2006).

Finally, the tyrosine residue, Y1096, is specific to only one of the RET isoforms, RET 51. The
phosphotyrosine Y1096 binds to Grb2, which leads to recruitment of Gabl or Gab2 to activate
the PI3K/Akt pathway (Liu et ah, 1996). Alternatively, Y1096 may recruit Ceasitas B-lineage
Lymphoma (CBL) and was shown to be required for ubiquitination and degradation of RET 51
(Calco et ah, 2013).

TYROSINE KINASE INHIBITORS
The kinase domain, specifically the binding sites and the mechanism by which they regulate
downstream signaling represents targets for drug discovery. Small-molecule tyrosine kinase in
hibitors (TKIs) focus on the ATP-binding sites found on the intracellular kinase domain of RTKs
and inhibit signaling by blocking phosphotransferase activity (Noble et al., 2004). While there is
no RET-specific inhibitor present, there are multikinase inhibitors that have proven to work
against RET. For instance, Vandetanib (ZD6474) proved to have potent inhibitory effects against
the kinase domain of RET although it was originally developed as an epidermal growth factor
receptor (EGFR) inhibitor. The inhibitor suppressed the secretion of calcitonin in 80 percent of
the patients with sporadic or familial MTC and the remaining 20 percent were partial responses
induced by the inhibitor (Carlomagno et al., 2003). Vandetanib binds to RET whether it is in its
phosphorylated or unphosphorylated state with equal affinity, explaining its inhibitory effects
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against other mutated residues. While some residues have demonstrated resistance towards vandetanib, it is to the date the most successful anti-RET inhibitor and was approved for treatment of
locally and advanced MTC tumors (Wells et ah, 2012). Chow et al., 2007 described Sunitinib
(SU011248) as a multikinase inhibitor that had successfully transitioned from its molecular design
to an approved target-therapy as it effectively inhibited advanced RET-mediated renal carcinoma
during phase II clinical trials.

Other inhibitors have also been identified with anti-RET activity, but have had varying results
including Cabozantinib (XL-184) Zhang et al., 2010) Sorafenib (BAY 43-9006) (Carlomagno et
al., 2006) and Motesanib (AMG 706) (Sherman et al., 2007). Other drugs have proven less effec
tive as a RET inhibitor although described to work against RET-mediated malignancies. For ex
ample, Imatinib (ST1 571), another multikinase inhibitor was described to block RET-mediated
MTC tumor growth. In vitro, phosphorylation of the Y1062 was blocked in the presence of Ima
tinib. RET expression was affected with increased exposure to Imatinib, which lead to a decrease
in cell growth and thus blocked tumor proliferation (de Groot et al., 2006). The concentration of
Imatinib used to achieve results in vitro were considered far too elevated to attempt in target-thera
py of MTC. In agreement, clinical trials of this drug proved to be ineffective, as the patients test
ed either had stable diseases, reduced doses or stopped treatment because of toxic effects (de
Groot et al., 2006).

RET DEPENDENT TRANSCRIPTION CANDIDATES
Sproutyl (Spryl)
Sprouty (Spry) proteins represent a class of ligand-inducible antagonists of the RTK-dependent
signaling pathways. Members of the Spry family are involved in anti-proliferation activity, inhibi
tion of migration, favoring of differentiation, and promotion of survival. In Drosophila, Spry
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inhibits FGFR and EGFR signaling during trachea and eye development (Hacohen et al., 1998).
While it is known that Spry proteins suppress Ras-Erk signaling via RTKs, the exact mechanism
by which Spry proteins function biochemically is not entirely understood (Mason et al., 2006).
Specifically, because the method in which Spry proteins interact with components of RTK signal
ing pathways to induce signaling is unclear. While Spry proteins have been described in the etiol
ogy of several RTK-mediated diseases and disorders, the present study will focus only on the
Spryl isoform. Spryl has been described as a negative regulator of GDNF/RET-mediated kid
ney induction and as a candidate tumor-suppressor gene in MTC, respectively (Basson et al.,
2005; Macia et al., 2012).

Spry was first identified in D. melanogaster while genetically screening for regulators of tracheal and
eye development (Hacohen et al., 1998). Four mammalian Spry homologs were identified based
on similarity with the Drosophila Spry sequence. The Spry family includes four family members,
Spry 1-4, and there are three conserved sequences found across all four Spry proteins, including a
tyrosine kinase-binding (TKB) binding motif, a serine-rich motif (SRM) and a cysteine-rich do
main (CRD) (Hacohen et al., 1998). The mammalian Spry proteins are similar to the Drosophila
Spry in the cysteine rich C-terminus, but differ in the N-terminus. The N-terminus of Spry rep
resent a conserved sequence that promotes its ability to inhibit signaling (Hanufusa et al., 2002;
Mason et al., 2006). The Spry genes encode relatively small proteins, approximately 63 Kda in
Drosophila and 32-34 Kda in mammals (Kim et al., 2004). Tyrosine phosphorylation of Spry
proteins is specific to the isoform, the growth factor and cell type, suggesting that Spry proteins
are functionally different (Mason et al., 2006). The expression pattern of mammalian Spry pro
teins was described in embryonic development as well as in adult tissue, and near fibroblast
growth factor (FGF) signaling complexes associated with mesenchyme-to-epithelial transition
(Chambers and Mason, 2000).
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The role of the Spryl has been described in the development of different organs, in particular,
kidney development and RET-mediated ureteric branching (Gross et al., 2003; Basson 2005). In
mice, Spryl is expressed in the developing metanephric mesenchyme that later becomes the
nephron and in the branching UB that later becomes the collecting system in the kidney (Gross et
al., 2003). In addition to RET and G FR al, several other genes such as W ntl 1 are co-expressed
specifically in the UB tips (Kispert et al., 1996). Spryl behaves as a negative regulator of ureteric
branching in kidney development via G D N F/RET/W ntl 1 in the Ras-Erk/MAPK pathway (Bas
son et al., 2005). Basson et al. showed that mice with non-functional Spryl have multiplexed dysplastic kidneys with enlarged ureters and numerous UBs branching at random site along the WD
(Basson et al., 2005). This phenotype results from failure of GD NF/RET signaling in the prolif
erating WD that leads to UB induction. An explanation for the phenotype is that increased RET
signaling in the absence of Spryl leads to hyper activation of the Ras-Erk/MAPK pathway (Bas
son et al., 2005).

The opposite phenotype is observed in non-functional RET mutations. Mice with non-functional
RET fail to develop kidneys during birth. Further, mutated Y1062 in which UB induction is
blocked by decreased Ras-Erk activity also results in renal agenesis (Basson et al., 2005). An ex
planation for the phenotype observed is that in stimulated conditions, the Ras-Erk pathway is ac
tivated, followed by translocation of phosphorylated ERK to the nucleus, where it is activates
transcription of Spry (Mason et al., 2006). Simultaneously, Spry is translocated to the plasma
membrane where it is tyrosine phosphorylated by Src kinase activity. In this negative feedback
mechanism, Spry suppresses the Ras-Erk pathway by inhibiting Ras activity (Gross et al., 2003).
Loss-of-function mutations of Spryl and RET respectively, are opposite examples of defects to
the kidneys and urinary tract that are caused from misregulation of the Ras-Erk pathway (Basson
et al., 2005). The non-functional Spryl and RET phenotypes can be rescued (Rozen et al., 2009),
Page 28 of 85

mice that lacked Y 1062 activity and Spryl demonstrated morphological corrections for the renal
defects seen in the individual non-functional phenotypes. Since Y 1062 is a multi-adaptor docking
site that can lead to PI3K/Akt and Ras-Erk/MAPK signaling, the morphological correction sug
gests UB branching may be achieved through RET-mediated signals other than those associated
with Y 1062.

A common outcome of aberrant expression of RTKs aside from development defects is malig
nancy. Given the Spry family’s behavior as negative regulators has prompted studies to address
the role of these proteins in cancer. The expression of Spryl has been shown to be down regulat
ed in breast cancer, prostate cancer, and cardiovascular diseases with minimal explanation as for
the mechanism by which Spryl functions. Recently, Macia et al. have proposed Spryl as a candi
date tumor suppression gene in MTC in a mouse model (Macia et al., 2012). The expression of
Spryl was traced to the thyroid glands from the embryonic state well into adulthood. Non-func
tional Spryl leads to calcitonin-producing C-cell hyperplasia, which is the primary reason for
MTC. However, non-functional Spryl did not lead to MTC, but rather C-cell hyperplasia alone
(Macia et al., 2012). Additionally, Spryl reduced proliferation of oncogenic RET-expressing cells
by inducing cellular senescence. Macia et al., suggested that Spry-mediated senescence could ex
plain the tumor suppression, but the mechanism by which expression of Spryl induces senescence
is not clear.

Protein Tyrosine Phosphatase Non-receptor Type 11 (PTPN11) (SHP2)
The phosphatase SHP2 is a downstream signaling component of RET whether by GDNF stimu
lation of the wild type receptor or by RET mutant forms (Kurokawa et al., 2001). However, the
biochemical function of SHP2 and the signaling components surrounding its activity are not en
tirely understood. Although the mechanism is not entirely understood, it is believed SHP2 is re-
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lated to Spryl and a transcription factor downstream of RET, ETV4, while the transcriptional
regulation of the associated signaling partners remain unclear.

The Src homology 2 domain-containing phosphatases (SHPs) are a sub-family of non-receptor
protein tyrosine phosphatases that are conserved between vertebrates and invertebrates. There
are two mammalian members SHP1 (encoded by PTPN6) and SHP2 (encoded by PTPN11) and
both have conserved sequences including two SH2 domains, a protein tyrosine phosphatases
(PTP) domain, a C-terminal tail with tyrosyl phosphorylations sites and a proline rich motif (Neel
et ah, 2003). The PTK phosphorylation and PTP dephosphorylation represent a signaling motif
of RTKs. Under normal conditions, SHP2 has low catalytic activity because the SH2 domain
and PTP domain keep it auto-inhibited. The auto-inhibition is released when the SH2 domain
binds to a phosphotyrosine on the activated receptor or scaffolding proteins. SHP2 is ubiquitously
expressed and functions as a signaling component of RTKs by promoting activation rather than
down-regulation of signaling pathways. Mutations in PTPN11 results in Noonan, LEOPARDS
syndrome and leukemia. Non-functional SHP2 mutations results in early embryonic defects in
mice. Neel et al., 2003 has shown SHP2 is important for the development of the central nervous
system and neural crest cells.

Recent studies suggest that SHP2 promotes the activation of Ras in the Erk/MAPK pathway.
PTPs are thought to play opposing roles of PTKs in signal transaction and assumed to be nega
tive regulators. While phosphatase activity is needed for SHP2 to promote activation of the
pathway, the exact dephosphorylation targets are not clear. In a proposed method, SHP2 com
petes with Spry land FRS2 adaptor proteins for binding to the Grb2-SOS signaling complex on
Y1062 to promote Erk/MAPK activation (Hanafusa et ah, 2004). Another study suggests SHP2
promotes the Ras-Erk/MAPK signaling pathway by inactivating phosphorylation sites on Spryl
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(Jarvis et al., 2006). It has also been concluded that SHP2 acts downstream of GDNF/RET-mediated signaling in branching morphogenesis during kidney development.

Incoranato et al., studied the interactions between mutant RET and the two phosphatases, SHP1
and SHP2, in the rat phenochromocytoma cell line, PC 12 cells (Incoranato et al., 2004). The
RET mutations studied included cysteine residue 634 and methionine residue 918 causing MEN
2A and MEN 2B, respectively. It was concluded the complexes formed by SHP2 and the mutant
RET were found outside the lipid rafts (Incoranato et al., 2004). Hereby concluding the SHP2mediated signaling occurs outside the raft compartment.

In mice, non-functional SHP2 produces a phenotype similar to that of non-functional RET muta
tions in which there is reduced UB branching and reduced kidney size. In situ hybridization on
sections of the kidney showed down regulation of RET target proteins including W ntl 1 and tran
scription factor ETV4 (Willecke et al., 2011). Studies have shown ETV4 signals are essential for
RET signaling, but are down regulated in nonfunctional SHP2 mice which may occur via the
PI3K/Akt pathway (Besset et al., 2000). The development of the kidneys was then observed in an
organ culture. The reduced UB branching phenotype on the explant remained the same even
after GDNF stimulation. In agreement with other studies, ERK/M APK signaling was reduced in
the UB bud tips of the mutated explants (Willecke et al., 2011). Lack of SHP2 in the UB prevents
mice with non-functional Spryl from developing numerous UB induction sites. In summary,
SHP2 may act downstream of Spryl in the GDNF/RET signaling pathway (Willecke et al.,
2011).
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ETS Translocation Factor Variant 4 (ETV4)
Several genes described to be important during kidney development are downstream regulators of
the G D N F /G F R al/R E T signaling pathway. Recently, Fu et ah, described the role of overlap
ping ETV4 and ETV5 in the developing mammalian kidney, specifically in the UB tips during
branching morphogenesis (Fu et ah, 2009). ETV4 and ETV5 are co-expressed during kidney
formation in a similar pattern as RET in the Wolffian duct, UB outgrowth and UB tips. In mice,
nonfunctional Etv4 and non-functional ETV5, together, result in phenotypes similar to the non
functional RET phenotypes. Additionally, those phenotype resemble the nonfunctional SHP2
phenotypes (Willecke et al., 2011). That is, the absence of both Etv4 alleles and a single Etv5 al
lele displayed renal agenesis whereas mice with a variation of the mutation displayed different
degrees of kidney reduction and UB branching (Fu et al., 2009). Further analysis demonstrated
the PI3K/Akt pathway important for ETV4 and ETV5 expression in UB tips whereas the RasErk/MAPK and PLG pathways did not affect the expression of these genes.

There are 28 human ETS genes and their homologues are found across vertebrates and inverte
brates. The polyomavirus enhancer activator 3 (PEA3) subfamily of ETS transcription factors
consists of three members ETV1 (Ews), ETV4 (Pea3) and ETV5 (Erm). The defining characteris
tic of the encoded proteins is the ETS domain that has three conserved a helices, and four an
tiparallel [3-sheets. The ETS domain DNA binding motif is approximately 85 amino acids long
and binds to DNA sequences with a 5 -GGA(A/T)-3' (Sharrocks et al., 2001). There is specula
tion about the way in which the ETS transcription factors regulate gene expression of specific
genes as they all potentially bind to the same DNA target. Possible reasons include tissue or celltype specificity, the sequence surrounding the 5 -GGA(A/T)-3' sequence or the ability of the
transcription factors that bind in close proximity to the ETS proteins (Oh et al., 2012). Expres
sion of ETV1, ETV4 and ETV5 has been traced in the development of numerous organs from
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the embryonic stages well into adulthood. The expression of two closely related genes, ETV4 and
ETV5, has been seen in the branching morphogenesis of organs including the lung, mammary
gland, salivary gland and the UB of the developing kidney (Chotteau-Lelievre, et al., 2003). The
co-expression of these two genes has been demonstrated to be essential in neuronal, spermatagonial and limb development (Oh et al., 2012). ETV4 was identified as a GDNF-RET target in mo
tor neurons during limb development in the chicken (Hasse et al., 2002). It was shown that
GDNF induces expression of ETV4, but only in a restricted subset of cervical motor neurons
showing the spatial restriction of ETV4 response (Hasse et al., 2002).

While many proteins associated with the RET signaling pathway have been identified and dis
cussed in the context of developmental biology, the transcriptional changes induced by the wild
type receptor, particularly with respect to these signaling proteins in neuroblastoma cells, is less
clear. The molecular mechanism(s) that connects the mutations or mutated sites on the receptor
to the disease phenotypes are not entirely understood, in part, because the transcriptional changes
of the putative signaling proteins involved in the proposed mechanistic pathways remain elusive.
Analyzing the expression levels of each gene using real-time quantitative PCR in response to the
activation of RET, will aid in elucidating RET-mediated mechanisms that contribute to these dis
eases, and understanding the role of RET on downstream signaling and cellular function. In the
present study, the gene expression of Spryl, SHP2 and ETV4 in response to the activated wild
type receptor RET is presented.
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MATERIALS and METHODS
Primer Design
All primers were designed based on published genomic sequences obtained from NCBI Genebank
or published papers using Primer-Blast. The primers are listed as three candidate genes followed
by two housekeeping genes.
Gene name: (Spryl) Sprouty homolog 1
NCBI accession number: NM_001258038
forward primer, 5-ACATGGCAGTGGCAGTTCGT-3
reverse primer, 5-GTCTTGGTGCTGTCCGAGGAG-3
Amplicon size (bp) 194

Gene name: (Shp2) Tyrosine-protein phosphatase non-receptor type 11
NCBI accession number: NM_002834
forward primer 5-CCGGACAGGGACGTTCATTG-3
reverse primer: 5-GCTTGTGTCTGGACCATCCC-3
Amplicon size (bp) 135

The primers for Etv4 were designed according to (Pellecchia et al., 2012).
Gene name: (Etv4) ETS translocation variant 4
NCBI accession number: NM_()01986.2
forward primer 5-GCTCGCTGAAGCTCAGGT-3
reverse primer 5-TCCTTCTTGATCCTGGTGGT-3
Amplicon size (bp) 112

The housekeeping genes GAPDH and f-l-Actin were designed according to (Sikand et ah, 2012).
Gene name: (GAPDH) Glyceraldehyde 3-phosphate dehydrogenase
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NCBI accession number:
forward primer 5-ACCCACTGCTGCACGTTTGAC-3
reverse primer 5-TGTTGCTGTAGCCAAATTCGTT-3
Amplicon size (bp) 100

Gene name: (Actb) [i-Actin
NCBI accession number:
forward primer 5-GCCGGGACCTGACTGACTAC-3
reverse primer 5-TTCTCCTTAATGTCACGCACGAT-3
Amplicon size (bp) 100

Cell Culture
Human neuroblastoma cell line SK-N-SH [American Type Culture Collection (ATCC
#H TB-11)] and were cultured in EMEM supplemented with 10% FBS according to manufactur
er’s recommendations. All cells were maintained at an atmosphere of 37°C with 2% relative hu
midity and 5% C O 2. Cells were passed from T-125 flasks to

6

well plates at a concentration of le 6

cells/well and grown overnight. The plates were then aspirated, rinsed with PBS, and starved in
serum free medium at 2 hours. Following the serum starvation, the cells were treated with serum
free medium containing the GDNF growth factor (Promega, cat. No. #G2781). The GDNF
treatment was diluted to final concentrations of lng/m L or 0. lng/m L in serum free media for
subsequent experiments. Cells were collected at 0 hours, 2 hours, 4 hours,

6

hours,

8

hours and

12 hours, and harvested for RNA extraction at the end of each time interval tested. RNA was
extracted using a Trizol-based method. Total RNA was resuspended in sterile DEPC treated
water and quantitated by O D 260. T he final concentration of the RN A was diluted prior to
being stored at -80°C.
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Reverse Transcription cDJVA synthesis
Extracted total RNA was subjected to reverse transcription prior to polymerase chain reaction in
the two-step protocol. The reverse transcriptase reaction was performed using oligo(dT) primers
obtained from Invitrogen Life Technologies. In brief, a 20 pL reaction was set up using 10 pL of
sterile DEPC treated H 2O, 1 pL of oligodT primers, 1 pL of 2.5mM deoxynucleotide triphosphate
dNTP mix, 1 pL of total RNA. The reactions were dispensed in 8 -strip PCR tubes and sealed
with domed caps and amplification was carried out using Applied Biosystems Veriti Thermal Cy
cler using the following conditions: 60°C for 3 minutes followed by 4°C for 1 minute. The reac
tion was paused and the remaining reagents were added to the reaction, 4 pL of Invitrogen 5X
Buffer, 2 pL of Invitrogen DTT, 1 pL of Invitrogen RNAase OUTand 1 pL of Invitrogen SuperScript II Reverse Transcriptase and cDNA synthesis continued under the following conditions:
42°C 30 minutes, 70°C 5 minutes. The sequence specific lyophilized primers obtained from Invit
rogen were diluted in autoclaved H 2O to make lOOpM stock solutions, which were then diluted in
autoclaved H 2O to make 1OpM working solutions. The reverse transcriptase reaction was per
formed according to the conditions described in the previous section. Unlike the primer oligo(dT)
reaction, the sequence specific reaction only requires a reverse 3’ primer for cDNA synthesis.

Standard Polymerase Chain Reaction (PCR)
The PCR reactions were prepped using reagents obtained from Invitrogen and Sigma-Aldrich. In
brief, a 25 pL reaction was set up containing: 15 pL nucleated free PCR grade autoclaved H 2O, 1
pL of 2.5mM deoxynucleotide triphosphate dNTP mix, 1 pL of 10 pM sequence specific forward
and reverse primers obtained from Invitrogen, 5 pL Sigma 10X PCR Buffer, 1.5 pL of 1.5mM
Sigma MgCb, 1 pL of cDNA template and 0.5 pL. of 5 U /pL Sigma Taq Polymerase. The reac
tions were dispensed in 8 -strip PCR tubes and sealed with domed caps and amplification was car
ried out using Applied Biosystems Veriti Thermal Cycler using the following conditions: 1 cycle of
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95°C for 5 minutes, followed by 40 cycles of 95°C for 30 seconds, 58°C for 30 seconds, and 72°C
for 1 minute, followed by 1 cycle of 72°G for 7 minutes. The experiments included ‘no reverse
transcriptase’ and ‘no template’ controls. The PCR conditions were then altered to 1 cycle of
95°C for 2 minutes, followed by 35 cycles of 95°C for 15 seconds, 55°C for 15 seconds, and
for 45 seconds, followed by 1 cycle of

6 8 °C

6 8 °C

for 5 minutes. The annealing temperature was altered

to the melting temperature of each gene, respectively.

Gel Electrophoresis
1% and 1.5% agarose gels were used for the gel electrophoreses reactions. The gels were pre
pared with lg or 1.5g agarose into lOOmL of the respective buffer used in the experiment either
IX TAE or IX TBE which were diluted from 50X TAE or 10X TBE stock solutions, respectively.
The components of the buffers included: (TAE) Tris Base, Glacial Acetic Acid, Na 2 EDTA, pH
~8.5; (TBE) Tris Base, Boric Acid and 0.5M EDTA, pH ~8.0. The running buffer used in the
reactions were the buffer used to make the gel and stained with ethidium bromide (EtBr). 10 pL
of the PCR product were diluted with 3 pL of DNA Loading Dye, 10 pL of the mixture were
loaded in each respective well on the gel. The gel ran for approximately 45 minutes at 100 volts.
Results were analyzed using the Launch TS Software on the UVP Ultraviolet Gel Imaging Sys
tem.

Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)
Two different approaches were employed for qRT-PCR, SYBR and TaqMan assays. The real
time PCR reactions were prepped using Brilliant SYBR Green Master Mix including ROX pas
sive reference dye obtained from Applied Biosystems. In brief, a 25 pL reaction was set up con
taining 12.5 pL of 2X SYBR Green PCR Master Mix, 1.5 pL of 10 pM of each of the sequence
specific forward and reverse primers, 1 pL of 1 in 5 diluted template cDNA synthesized from
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RNA extracted from SK-N-SH treated neuroblastoma cells, and 9.5 pL of nucleated free PCR
grade H 2O. The reactions were dispensed in qPCR 8-strip flat-capped tubes and amplification
was carried out using Applied Biosystems StepOne Plus Real-Time PCR System using the follow
ing conditions: 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1
minute. The experiment included a ‘no reverse transcriptase’ control. Otherwise, the real-time
qPCR reactions were set up using Taqman RNA-to-Ct 1-Step Kit obtained from Applied Biosys
tems with 900nM primers (forward and reverse) and 250nM probe. In brief, a 10 pL reaction was
set up containing 5 pL of TaqMan RT-PCR 2X, 3 pL of sterile DEPC treated H 2O, 0.5 pL of
20X Taqman Gene Expression Assay for each respective gene being tested, 0.5 pL of RT Taq
man Enzyme diluted to 20X and 1 pL of 1 in 10 diluted lOOng/mL RNA template. The reac
tions were dispensed into 96-well optical plates and sealed with Applied Biosystems sealing tape
and amplification was carried out using Applied Biosystems StepOne Plus Real-Time PCR Sys
tem using the following conditions: 48°C for 15 minutes, 95°C for 10 minutes, followed by 40 cy
cles of 95°C for 15 seconds and 60°C for 1 minute. Three technical replicates were performed
per RNA sample along with a ‘no template’ control. Specificity and amplification were confirmed
by running the samples on a 1% agarose gel. Gene expression was quantified by using the relative
standard curve method and AACt Livak method. Expression of Spryl, Shp2 and Etv4 were
normalized to either p-Actin or GAPDH expression, relative to treatment. The treatments in
cluded, serum-free (untreated) control, 4-hour serum treatment and 4-hour 100 ng/m L GDNF
treatment. Ten-fold serial dilutions of lOOng/mL RNA were used to construct a standard curve,
including, (IX, 0. IX and 0.0IX ). The mean and ± standard deviation of the candidate genes
normalized to the housekeeping, endogenous controls were calculated from four independent ex
periments.
The TaqMan Gene Expression Assays used are listed below:
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Gene Name sprouty homolog 1, antagonist of FGF signaling (Spryl)
NCBI Location Chromosome Chr.4: 124317956 - 124324910
NCBI Accession no. NM_001258038.1 Amplicon Length 103
Dye Label and Assay Concentration: FAM-MGB / 20X

Gene Name: protein tyrosine phosphatase, non-receptor type 1l(Ptpnl 1)
NCBI Location Chromosome Chr.12: 112856536 - 112947717
NCBI Accession no. NM_002834.3 Amplicon Length 78
Dye Label and Assay Concentration: FAM-MGB / 20X

Gene Name ets variant 4 (Etv4)
NCBI Location Chromosome Chr. 17: 41605211 - 41623762
NCBI Accession no. NM_001079675 Amplicon Length 70
Dye Label and Assay Concentration: FAM-MGB / 20X

Gene Name: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Endogenous Control
(probe, non-primer limited)
NCBI Accession no. NM_002046.3 Amplicon Length 122
Dye Label and Assay Concentration: FAM-MGB / 20X

Gene Symbol: (3-actin (Actb) Endogenous Control
NCBI Location Chromosome Chr.7: 5566779 - 5570232
NCBI Accession no. NM_001101.3 Amplicon Length 63
Dye Label and Assay Concentration: FAM-MGB / 20X
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RESULTS
PRIMER DESIGN of CANDIDATE GENES
In order to evaluate expression changes of specific genes in response to RET activation, RT-PCR
and real-time PGR were performed. Primer design is an essential application component for re
verse transcription polymerase chain reaction (RT-PCR) in order to yield successful amplification
of a target sequence. The reaction requires two PGR primers that are specific for the sequence
amplified. When measuring gene expression it is also important for the primers to differentiate
between cDNA and genomic DNA amplification. The forward and reverse primers designed for
Spry 1 span a single exon in the mRNA sequence (figure no.3). The forward Shp2 primer was
designed to span an exon junction while the reverse primer lies within a single exon to reduce the
risk of false positives from amplifying genomic DNA (figure no.3). Theses primers will anneal to
cDNA from spliced mRNAs, but not to genomic DNA. Likewise, the forward primer designed for
Etv4 spans an exon junction, while the reverse primer spans a different exon (Pellecchia et al.,
2012). The primers for target and reference genes were designed using Primer-Blast to have simi
lar properties so that they could be tested simultaneously in subsequent reactions. The primers for
(3-actin and GAPDH, were designed according to the primer sequences used for real-time QPCR
by (Sikand et al., 2012) (figure no.4). Both forward and reverse f.Uactin primers were designed
within a single exon. The forward and reverse GAPDH primers flank a region that contains an
intron towards the end of the mRNA sequence. The GAPDH primers were designed to bind to
different exons to promote amplification of cDNA such that genomic DNA contamination is
avoided. The PCR product amplified from the region of cDNA excluding introns, will be smaller
in size compared to a region containing introns. Thus, amplification of contaminating genomic
DNA should be eliminated.
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PRIMER CHARACTERIZATION of CANDIDATE GENES
Extracted total RNA (work by a different graduate student from the lab) was subjected to reverse
transcription followed by polymerase chain reaction in order to determine the specificity of the
primers designed. The synthesis of DNA from an RNA template, via reverse transcription, pro
duces complementary DNA, termed cDNA. The reaction requires an RNA template and a short
primer complementary to the 3’ end of the RNA sequence to direct the synthesis of the first
strand of cDNA. The cDNA template is then used for the polymerase chain reaction to exponen
tially amplify the target DNA sequence. The PCR product is then evaluated by gel electrophore
sis. In this method, an electrical field is applied such that the PCR product travels through the
gel, from negative end to the positive end, at a speed that is inversely proportional to the size of
the molecule. Thus, smaller fragments travel quicker than larger fragments.

The reverse transcription reaction was originally performed with oligo(dT) primers to synthesize
cDNA from the total RNA extracted from SK-N-SH Ing/m L GDNF-treated neuroblastoma
cells. While some genomic DNA contamination is possible, the purity of the total RNA is critical
in order to capitalize on the sensitivity of the technique. The purity of the starting total RNA
template was 1.64 A 2 6 O / 2 8 O . Oligo(dT) primers are nonspecific primers that offer flexibly of the
cDNA so that the cDNA, in a two-step reaction, may be used as template for subsequent poly
merase chain reactions with gene-specific primers, for genes in the present study. Oligo(dT)
primers initiate reverse transcription at the 3’ polyA tail of the transcript, but do not ensure that
the 5’ end of long mRNAs is converted to cDNA. In that case, a different priming method, ran
dom primers could be used to increase the probability that the 5’ mRNAs convert to cDNA, re
sulting in shorter cDNA fragments across the mRNA sequence. Transcriptase activity depends in
part, on the purity and integrity of the starting material, but also by secondary structures, which
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can obstruct the reverse transcriptase activity and lead to incomplete cDNA synthesis. The tem
perature of the reaction is equally as important for proper cDNA synthesis.

The primers for GAPDH and (3-actin were subjected to reverse transcription with oligo(dT)
primers followed by polymerase chain reaction as shown in (figure no. 5). The DNA ladder in the
first lane represents a marker of known DNA fragment sizes ranging from 0.1 base pairs (bp) to 10
kilo bases (kb). In the initial experiment, none of the experimental samples, including the ‘no re
verse transcriptase’ and ‘no template’ controls, showed any amplification (figure no.5). Therefore,
the use of oligo(dT) primers for reverse transcription proved to be ineffective as they did not lead
to the amplification of Gapdh and j3-actin. The lack of PCR product can be explained by poor
quality of PGR template, primer design or the reagents used in the reaction.

Sequence-specific primers can provide high specificity but the cDNA synthesized can only be used
to study the particular gene for which the primers were designed, unlike oligo(dT) primer depen
dent reverse transcription which can be used to study many possible genes. Gene-specific primers
were used in subsequent reactions to improve data analysis. In figure no. 6, lane 2, GAPDH am
plification was observed. Unfortunately, amplification was also seen in the ‘no reverse transcrip
tase’ and ‘no template’ control (lanes 3 and 4, respectively), suggesting that the amplification was
not mRNA specific. However, when amplifying for (3-actin, a much more specific signal was obtainined. While the intensity of the band is high and no distinct, lane 6 represents amplification
of (3-actin. The negative control reactions represented in lanes 7 to 9, suggest there is no genomic
DNA amplification or genomic DNA contamination in the sample. To confirm the amplification
of (3-actin was the correct size, 100 bp, subsequent experiments used 1.5% agarose gels. A higher
gel percentage has smaller pores, which, in turn, allow for more clear measurements of small
fragments.
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The specificity of the (3-actin primers was confirmed by single distinct bands present in lanes 2
and 5 (figure no. 7). This was accomplished by diluting the RNA template used in the reverse
transcription reaction to 1 in 10 diluted 100ng/mL and 1 in 5 diluted lOOng/mL. Seocnd, de
creasing the Taq polymerase volume froml pL in a 25 pL reaction to 0.5 pL. Lastly, the final
primer concentration was set to 0.6 pM per 25 pL reaction volume. The Taq polymerase and
final primer concentration modifications were maintained in subsequent experiments. The speci
ficity of Etv4 and Spryl primers were confirmed by distinct bands present in lanes 2 and 4, re
spectively (figure no. 8). The inclusion of (3-actin in this experiment served as a positive control.
Amplification of the genes were present in the ‘+ reverse transcriptase’ controls, but not in the ‘no
reverse transcriptase’ controls. The two separate experiments show the intensity of the band is
dependent, in part, on the concentration of RNA template used in the reverse transcription reac
tion.

|3-actin were subjected to reverse transcription with oligo(dT) primers in order to determine if the
modifications made to the reaction components would yield cDNA synthesis using oligo(dT)
primers. (3-actin was chosen as it maintained positive results in the experiments thus far. Figure
no.9 shows amplification of (3-actin with sequence-specific primers and oligo(dT) primers in lanes
2 and 6, respectively. Reverse transcription reactions were tested using oligo(dT) primers followed
by polymerase chain reaction with other sequence specific primers, but the results were not repro
ducible (data not shown).

The specificity of Shp2 was confirmed by the band present in lane 8 (figure no. 10). In this exper
iment (3-actin and GAPDH served as controls. The inclusion of Etv4 in this experiment owed to
the PCR product smear present in lane 4 in figure no.8. Smearing can be can caused by too
much starting template evident in the (left) undiluted RNA experiment, which was corrected by
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the (right) 1 in 5 diluted lOOng/mL RNA template (figure no.8). Also, because suboptimal primer
concentrations can affect band quality, the final concentration of the primers in this experiment
were set to 0.4 pM. The number of cycles during the polymerase chain reaction were also re
duced from 40 to 35. The agarose gel was stained with EtBr overnight and visualized the follow
ing morning, but there was no amplification of Etv4 seen in lane 4 (figure no. 10).

Subsequent experiments were performed to confirm the specificity of the primers for the appro
priate sequences. The experiments continued to use the following final concentrations: 0.6 pM
forward and reverse primer, lU /25pL Taq polymerase, 0.125 mM dNTPs, 1.5mM MgCl2+,in
cluded 35 cycles during polymerase chain reaction. The reverse transcription reactions was per
formed with sequence-specific reverse primers and 1 in 5 diluted 100ng/mL RNA templates, all
of which proved successful in preceding experiments. Such conditions were used in combination
with increasing annealing temperature to avoid primer dimers or unspecific DNA binding. How
ever, distinct amplification of the genes were achieved in inconsistent patterns (figure no. 11), re
gardless of the optimization method and thermal cycler conditions used.

TRANSCRIPTIONAL PROFILING of CANDIDATE GENES
Because of the difficulties in obtaining reproducible results using standard RT-PCR subsequent
experiments used real-time PCR. Real-time quantitative polymerase chain reaction, also referred
to as real-time PCR, or qPCR, provides a method for determining the amount of a target se
quence present within in a sample. The reaction is characterized by the point at which amplifica
tion of the target sequence achieves a significant level of fluorescence as the reaction progresses,
thus, in real time, rather than by end-point analysis as in standard PCR. Irrespective of the real
time PCR method used, the data is read as the number of PCR cycles necessary to achieve ampli
fication that is detected by florescence signals. The amplification curve can be divided into four
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parts, the baseline, the exponential phase, the linear phase and the plateau phase. The baseline
refers to the earlier cycles where there is no significant change in fluorescence signal. The thresh
old is set above the baseline in the linear phase, but sufficiently low to be within the exponential
phase of the amplification curve. The accumulation of fluorescence becomes significantly greater
compared to the baseline during the exponential phase. The relative measure of the concentra
tion of the template in the PGR reaction is read as the intersection between the amplification
curve and the threshold value. This is termed cycle threshold (Gt) value.

Quantification may either be absolute or relative depending on the experimental goals. In the
present study, relative quantification was used to compare changes in gene expression, to deter
mine the fold-difference in expression. This method requires normalization of fluorescence sig
nals for the target being tested against an endogenous control. An endogenous control is a refer
ence gene that should be expressed at similar levels in all samples tested. Housekeeping genes can
be used as endogenous controls as they are involved in basic cellular functions and assumed to be
constitutively expressed regardless of treatment.

In a two-step reaction (figure no. 13), cDNA was first synthesized with sequence-specific primers
and then subjected to real-time PCR using the SYBR Green method. SYBR green binds to the
double stranded DNA by intercalating between adjacent base pairs. This method quantifies
cDNA, reverse transcribed from RNA, by measuring the florescence signal emitted by the SYBR
green dye at the end of each cycle bound to double stranded DNA (Wittwer et al., 1997). While
quantification of (3-actin and Spryl was obtained, Spryl did not yield expected results. The Ct
value for the ‘+ reverse transcriptase’ reaction did not register above background and amplifica
tion of Spryl was not detected. Instead, amplification was detected in the ‘no reverse transcrip
tase’ reaction probably owing to recognition of nonspecific double stranded DNA. SYBR Green

Page 45 of 85

experiments were continued with different annealing temperature, primer concentrations and
cDNA dilutions (data not shown), but proved to be unsuccessful.

To improve gene expression data analysis, a different real-time PCR method was employed using
the TaqMan method. TaqMan real-time PCR uses specific primers to quantify cDNA, where 5’3’ exonuclease activity of Taq DNA polymerase degrades 5’ fluorophore group of the probe and
the florescence emitted is measured at the end of each cycle during exponential stages of the PCR
reaction (Livak et al., 1995). The probe contains a fluorescent FAM dye, termed a fluorophore,
on the 5’ end and a minor groove binder (MGB) quencher molecule on the 3’ end. The proximity
of the quencher molecule to the fluorophore keeps it from fluorescing due to fluorescent reso
nance energy transfer (FRET) (Livak et al., 1995). In the presence of the template, the probe
bind downstream of the forward primer and during the extension phase of PCR is removed by
the 5’ nuclease activity of Taq polymerase. When the probe is removed, the fluorophore and
quencher are separated allowing the fluorescence signal to be detected as the quencher no longer
inhibits its activity. This continues at each cycle during the reaction and the accumulation of sig
nal emitted from the fluorophore is proportional to the amount of template present in the sample.

The previously designed sequence-specific primers were not used for the Taqman real-time PCR
reactions. Instead, predesigned primer and probe gene expression assays were selected. The real
time PCR reaction was performed as a one-step reaction in which the reverse transcription and
polymerase chain reaction were carried out consecutively in a single reaction tube. The real-time
PCR reactions were performed using technical replicates where the template used derived from
the same SK-N-SH RNA extraction. Three replicates were used to control for validity of the
method. The bar height indicates the average expression and ± standard deviations of the genes
in response to the experimental conditions: untreated (serum-free), 4hr serum treatment and 4hr
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GDNF treatment, respectively (figure no. 14). The data is presented as the average Ct value which
denotes the cycle at which fluorescence signal, indicative of the template present, was first signifi
cantly greater compared to the baseline.

GAPDH and (3-actin represent the endogenous controls in the present study. While the average
Ct values are consistent for GAPDH across the treatments (22.95, 22.48, 22.10), they are not for
(3-actin (30.55, 27.15, 30.21). In the target genes, the average Ct for serum is lower and the aver
age Ct for GDNF is higher relative to the untreated (serum-free) control. While the resultant av
erages are graphed similarly for Spryl and Etv4, they are different for Shp2. The gene expression
of the housekeeping genes were compared by calculating the A in Ct average. The value is ex
pressed as the average Ct of the housekeeping gene subtracted from the average Ct of the target
gene. There is great disparity in the A in Ct average compared between the two housekeeping
genes (figure no. 14). When compared to (3-actin, Etv4 and Shp2 appear to have negative values
and Spryl has positive values. When compared to GAPDH, the A in Ct average results in posi
tive values for all of the genes.

Relative quantification requires a standard curve to compare the expression levels of a gene in a
treated sample versus an untreated sample. The untreated (serum-free) control was a reference
sample used as basis for relative quantification results. The template used to construct the threepoint standard curve was RNA extracted from SK-N-SH untreated (serum-free) neuroblastoma
cells. The cDNA reverse transcribed from RNA is expected to express both the target gene and
the housekeeping gene. Standard curves were plotted to known concentrations and then created
by performing real-time PCR on serial dilutions of the template. The highest concentration was
undiluted lOOng/mL RNA plotted as (IX) on the standard curve. When the initial concentration
of the template is high (IX), the Ct is reached at an earlier amplification cycle. The second conPage 47 of 85

centration was 1 in 10 diluted lOOng/mL RNA plotted as (0. IX) on the standard curve. The
most diluted template to construct the standard curve was 1 in 100 diluted 1OOng/mL plotted as
(0.0IX) on the curve. The Ct of the most diluted template is reached at a later amplification cy
cle. A linear regression of the Ct values derived from the template dilutions are plotted against
the log of the initial copy number. The regression line is used to determine the concentration of
the unknown samples from their Ct values relative to the standard. Figures no. 15-18 and 20-23
represent the standard curves for each gene plotted as grey boxes, respectively.

The results show aberrant fold differences when normalized to J3-actin (figure no. 19). The refer
ence gene should have stable expression levels in all samples and should not change with treat
ment. The serum treatment and GDNF treatment were tested using 1 in 10 diluted lOOng/mL
RNA (0. IX) to ensure the expression level of the template fell within the limits of the standard
curve, such that the Ct value is between the highest and lowest dilutions on the standard curve.
The unsuitability of P-actin as an endogenous control is reflected in the efficiency of the assays
(table no. 1). The efficiency of the assay is determined by the rate at which the PCR product is
detected and that is measured as a percentage. In table no. 1, the efficiency for [3-actin is well
above the accepted 110%, suggesting possible pipetting error in serial dilutions or co-amplification
of nonspecific product and in the second experiment, the efficiency is below 90% indicating suboptimal reaction conditions. The efficiency of an assay is generated from the standard curve.
Because the replicates were stochastic for all treatment conditions, the normalization to P-actin
resulted in incorrect relative quantification of gene expression.

A second efficiency measurement is the R2value. This value indicates how well the value of Y
(Ct) can be used to accurately predict the value of X (quantity) in a standard curve. The R2value
when close to 1 assumes there is a 2-fold difference between each Ct value on the standard curve.
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While the normalization to (3-actin was not considered, Shp2 showed a distinct difference in the in
response to GDNF treatment (figure no. 17). The earlier Ct values suggest a possible 2-fold upregulation of Shp2 in response to the activated RET receptor when compared to the untreated
(serum-free) control. While these results are interesting they were not reproducible in subsequent
experiments.

The results show minimal fold differences when normalized to GAPDH (figure no.24). The ex
pression of GAPDH in response to the three experimental conditions was uniform and the varia
tion between replicates was minimal (figure no. 20). In table no.2, the efficiency of GAPDH is
well above 110% in the earlier experiment, but within the acceptable range in latter experiments.
Because the replicates for each treatment were much less stochastic compared to j3-actin, relative
quantification of gene expression normalized to GAPDH was made possible.

DISCUSSION
In order to evaluate the transcriptional changes that might occur in genes associated with RET
dependent signaling, we studied the gene expression of RET-dependent signaling proteins in the
human SK-N-SH neuroblastoma cell line using real-time PCR. Initially, sequence-specific
primers were designed using Primer-Blast to amplify the genes Spryl, Shp2 and Etv4. Different
reverse transcription priming methods including oligo(dT) primers, random primers and se
quence-specific primers resulted in inconsistent amplification results (figure no. 5-12). While am
plification of the target genes was achieved with sequence-specific primers, the results were not
reproducible, despite continued optimization efforts. To improve data analysis real-time PCR was
performed using the SYBR Green method, but also proved unsuccessful (figure no. 12). To estab
lish whether the signaling proteins under study were either induced or repressed in response to the
activation of RET, TaqMan gene expression primer and probe assays were selected. The real-
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time PCR data was analyzed to show the relative changes in gene expression levels using the Livak
AACt method based on the 2 'AACl equation (Livak and Schmittgen, 2001). Relative quantifica
tion relates the expression of a gene in a given sample to that of another sample such as an un
treated control. The correction of experimental variability in a real-time PCR experiment is
achieved by normalization to an endogenous control, more specifically, a housekeeping gene.
Housekeeping genes are involved in basic cellular functions and assumed to be constantly ex
pressed at the same level regardless of treatment; however, the expression of (3-actin did not ex
hibit those properties (figure no. 15 and table no. 1). Variation in the expression of a housekeeping
gene can potentially mask the changes in expression of the target gene(s). Further, recent studies
have shown expression of the commonly used housekeeping genes including 18S RNA, GAPDH,
and (3-actin to vary under diverse conditions (Dheda et al., 2005). The unsuitably of (3-actin as an
endogenous control in the real-time PCR experiments resulted in normalizing gene expression
levels to GAPDH.

The gene expression normalized to Gapdh showed discrete fold differences, less than two-fold, in
response to the activated RET receptor when treated with GDNF for 4 hours (figure no 24). The
biological significance of a given-fold change is likely to depend on the gene and on the experi
mental context. A two-fold differential is a relatively small change, but considered functionally
significant in the development of the mammalian kidneys. The changes in gene expression lead
to functionally significant changes in the protein that cause profound developmental effects in the
kidney. The expression of Etv4 is upregulated by a 2.9-fold in response to GDNF-RET signaling
during kidney development and is essential for ureteric bud branching morphogenesis (Lu et al.,
2009). While the expression levels in that experiment were accessed via Affymetrix microarray
analysis, minimal fold difference of 0.24 and 0.61 were observed in neuroblastoma cells using
real-time PCR (Table no.2). Although direct comparison between real-time PCR reactions canPage 50 of 85

not be made, an average fold change of 0.42 is a small numeric value, indication of a weak re
sponse to 4-hour GDNF stimulation.

The expression of Spryl is upregulated by a 3.3-fold in response to GDNF-RET signaling in the
ureteric bud (Lu et al., 2009). However, those changes were not observed in neuroblastoma cells.
When normalized to (3-actin the fold difference ranged from 0.15 to 1.50 (figure no. 19) and when
normalized to GAPDH the fold difference ranged from 0.11 to 1.52 (figure no.24). The fold dif
ference is so small that functionally, it may be considered unimportant. One explanation for the
minimal change in gene expression is the use of the human SK-N-SH neuroblastoma cell line, as
there are genes that are only expressed transiently or only in certain tissues. In addition, the SKN-SH cells are a differentiated cell line and the developmental activity of the genes of interest,
Spryl, Shp2 and Etv4, were described early stages of kidney development. While neuronal and
kidney systems derived from neural crest cells and differentiate similarly, neuronal systems may
behave differently from kidney systems.

Further, transcription of these genes may not be dependent on RET activation alone, but rather
in combination with other ligands. It has been established that the SK-N-SH neuroblastoma cell
lines expresses RET, but different cell types express characteristic sets of transcriptional regulators.
Neuroblastoma cells have demonstrated to require TGF-P for GDNF expression in the RET sig
naling pathway as the GDNF family of proteins form a subdivision of the transforming growth
factor (3 (TGF-P ) superfamily (Mason, Ivor, 2000). The co-expression, of a ligand other than
GDNF may be necessary for gene expression of these signaling proteins. And because different
cell types often respond in different ways to the same extracellular signal.
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The Ct value in real-time PCR is a dependent variable affected by treatment and concentration
of template. The Ct values become less efficient at high dilutions because they are more sto
chastic in the presence of less template. While the template may have not presented an issue, it
seems likely that the time-course of GDNF stimulation would elicit a more signifiant change in
gene expression. Perhaps the Spryl, Shp2 and Etv4 genes are not expressed transiently or rapidly
in response to RET-GDNF signaling, but rather by late responses to longer stimulation with
GDNF. More time points, other that the 4-hour GDNF stimulation, are needed to elicit elevated
gene expression responses. Longer GDNF stimulation, such as 6-hour, 8-hour, 12-hour treatment
may promote transcription of the genes. Alternatively, in stimulated conditions, the RET recep
tor exists in a phosphorylated state, but the magnitude of the signal is not sufficient to transduce
the signal to the nucleus so that target proteins, including transcription factors, may be activated
to change patterns in gene expression.

The lack of biological replicates could have also contributed to the minimal changes in gene ex
pression observed. The use of technical replicates provided a limitation in this study as the data
represents a single group of RNA that was extracted from SK-N-SH neuroblastoma cells, there
fore the biological material analyzed is the same. The findings from these experiments only repre
sent that specific RNA extraction and measure the reproducibility of the results. To draw mean
ingful conclusions, independent biological replicates are needed. Biological samples in which dif
ferent RNA extractions from different SK-N-SH neuroblastoma cell cultures were stimulated with
GDNF and then subjected to real-time PCR for relative gene expression analysis. The findings
from such experiments would show similar patterns of gene expression and how those expression
patterns are differ between untreated (serum-free), 4-hour serum and 4-hour GDNF treatments.
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CONCLUSION
Because it has been proposed Etv4 may act downstream of Shp2 (Besset et al., 2000) and Shp2
may act downstream of Spryl (Willecke et al., 2011) in the GD NF/RET signaling pathway, it is
not surprising that the fold differences observed, for the genes tested, were similar in response to
GDNF and serum stimulation (figure no.24). Expression of the genes increase with serum stimu
lation and decreases in response to GDNF. These findings, show quantitatively minimal effect on
Spryl, Shp2 and Etv4 expression in response to 4-hour GDNF treatment in the human SK-N-SH
neuroblastoma cell line by real-time PCR. Our data, therefore, suggests that the fold difference is
too discrete to alter the physiological state of the cell or for the cell to have to compensate for the
change. The magnitude of the GDNF-RET signal, by 4-hour GDNF stimulation, is not trans
duced to the nucleus to activate transcription of GDNF-RET dependent proteins. Finally, tran
scription of these signaling proteins may not depend on RET activation alone. Future studies
include analyzing transcriptional changes of these signaling proteins in response to RET activa
tion with longer GDNF treatment times. Second, analyze the transcriptional changes of the sig
naling proteins in response to RET activation with co-expression of different ligands including
GDNF and TGF-fi. And third, the inclusion of biological replicates as opposed to technical repli
cates. All of which should elicit a significant change in expression and thereby, contribute to un
derstanding the role of RET in these RET-dependent signaling protein. In summary, the present
findings contribute to elucidating the role of RET on downstream signaling and in cellular func
tion.
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Figure No. 1 Schematic representation of RET receptor tyrosine kinase
The extracellular region of RET consists of four phylogenetically conserved cadherin-like do
mains (CLD) that are each 110 residues long, including a calcium binding site between CLD2 and
CED3, followed by a 120-residue cysteine rich domain (CRD) that is connected to the transmem
brane domain (TM). The intracellular region of RET begins with a 50-residue juxtamembrane
(JM) followed by a catalytic tyrosine kinase domain that is separated by a 14-residue linker region
and ends with the 100-residue carboxyl terminal tail that results in two functional RET isoforms
as a results of alternative splicing, RET 9 (short) and RET 51 (long).
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Figure No. 2 Schematic of Signaling Pathway Activity by the RET Receptor
The RET receptor is represented as the green structure at the raft compartment of the plasma
membrane. The assembly of the ligand, co-receptor and RET complex leads to dimerization.
Dimerization allows each monomer to auto-phosphorylate the tyrosine residues in orange on the
opposing monomer. Auto-phosphorylation activates the kinase activity of the receptor thereby
signaling activation of other components downstream. The black arrows represent the putative
pathways involving adaptor proteins, docking proteins, transcription factors and enzymes (left to
right): growth factor receptor bound protein 2 (GRB2), Grb2 associated binding typel (GAB1),
(AKT), lipid phosphoinositide 3-kinase (PI3K), phospholipase C gamma (PLC-y), protein kinase
C (PKG), protein tyrosine phosphatase, non-receptor type 11(PTPN11), (GRB2), sons of sevenless
(SOS), extracellular signal-regulated kinase (Erk) and activation of mitogen-activated protein ki
nase (MAPK), janus kinase and signal transducer and activation of transcription (JAK/STAT).
The candidate genes are represented in grey at their presumed location based on gene knockout
studies. The signal is transduced to the nucleus and transcription of growth-factor-responsive
genes is activated. The possible cellular outcomes are highlighted at the bottom of the figure.
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Figure No. 3 Standard RT-PCR Primer Design for Candidate Genes (listed top to bottom)
SPRY1 NM_001258038.1 - The forward and reverse primers both span an exon. The PCR
product length is 194 base pairs. The forward primer parameters: 20 nucleotides, 55% GC con
tent, and the melting temperature 62°C. The reverse primer parameters: 21 nucleotides 61% GC
content, and the melting temperature 61°C.
PTPN11 (SHP2) NM_002834.3 - The primer was designed so that half of the forward primer
hybridizes to the 3’ end of one exon and the 5’ end of the adjacent exon. The reverse primer
spans an exon. The PCR product length is 135 base pairs. The forward primer parameters: 60%
GC content, and the melting temperature 61°C. The reverse primer parameters: 60% GC con
tent, and the melting temperature 60°C.
ETV4 NM_001986.2 - The forward primer spans an exon junction while the reverse spans an
exon. The forward primer parameters: 18 nucleotides, 61% GC content, and the melting tem
perature 59°C. The reverse primer parameters: 20 nucleotides, 55% GC content, and the melting
temperature 55°C.
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Figure No. 4 Standard RT-PCR Primer Design for Housekeeping Genes (listed top to bottom)
ACTB NM_001 101.3 - The forward and reverse primers both span an exon. The PCR product
length is 100 base pairs. The forward primer parameters: 20 nucleotides, 65% GC content, and
the melting temperature 61°C. The reverse primer parameters: 23 nucleotides, 43% GC content,
and the melting temperature 60°C.
GAPDH NM_002046.3 - The forward and reverse primers flank an intron. The PGR product
length is 100 base pairs. The forward primer parameters: 21 nucleotides, 57% GC content, and
the melting temperature 61°G. The reverse primer parameters: 22 nucleotides, 40% GC content,
and the melting temperature 59°C.
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Figure No. 5 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed using undiluted 100ng/niL of RNA template and primer
oligo(dT) followed by polymerase chain reaction with primers specific for GAPDH and [3-actin.
The gel conditions are: 1% agarose gel in IX TBE ran at 100 volts for 45 minutes.
(1) DNA ladder
(2) GAPDH + reverse transcriptase
(3) GAPDH ‘ no reverse transcriptase’ control
(4) GAPDH ‘ no template’ control
(5) GAPDH + reverse transcriptase without Taq polymerase
(6) [3-actin + reverse transcriptase
(7) [3-actin ‘ no reverse transcriptase’ control
(8) |3-actin ‘ no template’ control
(9) [3-actin + reverse transcriptase without Taq polymerase
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Figure No. 6 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed using undiluted 1OOng/mL of RNA template using se
quence - specific reverse primer followed by polymerase chain reaction with primers specific for
Gapdh and (3-actin. The gel conditions are: 1% agarose gel in IX TBE ran at 100 volts for 45
minutes.
(1) DNA ladder
(2) GAPDH + reverse transcriptase
(3) GAPDH ‘ no reverse transcriptase’ control
(4) GAPDH ‘ no template’ control
(5) GAPDH + reverse transcriptase without Taq polymerase
(6) (3-actin + reverse transcriptase
(7) (3-actin ‘ no reverse transcriptase’ control
(8) (3-actin ‘ no template’ control
(9) (3-actin + reverse transcriptase without Taq polymerase
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Figure No. 7 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed using (left) 1 in 10 diluted 100ng/mL RNA template and
(right) 1 in 5 diluted 1OOng/mL RNA template with the (3-actin reverse primer followed by poly
merase chain reaction with primers specific for (3-actin. The gel conditions are: 1.5% agarose gel
in 1XTBE ran at 100 volts for 45 minutes.
(1) DNA ladder
1 in 10 diluted lpg/uL of RNA template.
(2) |3-actin + reverse transcriptase
(3) (3-actin ‘no reverse transcriptase’ control
(4) (3-actin ‘no template’ control
1 in 5 diluted lpg/uL of RNA template.
(5) (3-actin + reverse transcriptase
(6) (3-actin ‘no reverse transcriptase’ control
(7) (3-actin ‘no template’ control
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Figure No. 8 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed with (left) undiluted lOOng/mL RNA template and (right) 1 in
10 diluted 100ng/niL RNA template using sequence-specific reverse primers followed by poly
merase chain reaction with primers specific for Etv4, Spryl and and (i-actin. The gel conditions
are: 1% agarose gel in IX TBE ran at 100 volts for 45 minutes.
(1) DNA ladder
(2) Etv4 + reverse transcriptase
(3) Etv4 ‘no reverse transcriptase’ control
(4) Spryl + reverse transcriptase
(5) Spryl ‘no reverse transcriptase’ control
(6) (3-actin + reverse transcriptase
(7) P-actin ‘no reverse transcriptase’ control
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Figure No. 9 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed using 1 in 5 diluted 1OOng/mL of RNA template and
(left) sequence-specific reverse primer or (right) primer oligo(dT) followed by polymerase chain
reaction with primers specific for P-actin. The gel conditions are: 1.5% agarose gel in IX TBE
ran at 100 volts for 45 minutes.
(1) DNA ladder
Sequence-specific reverse primer
(2) [3-ac.tin + reverse transcriptase
(3) p-actin ‘no reverse transcriptase’ control
(4) P-actin ‘no template’ control
(5) P-actin + reverse transcriptase without Taq polymerase
Primer oligo(dT)
(6) p-actin + reverse transcriptase
(7) p-ac.tin ‘no reverse transcriptase’ control
(8) P-actin ‘no template’ control
(9) P-actin + reverse transcriptase without Taq polymerase
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Figure No. 10 Gel Electrophoresis: Agarose gel of RT-PGR product
Reverse transcriptase was performed with 1 in 5 diluted 1OOng/mL RNA template using se
quence-specific reverse primers followed by polymerase chain reaction with primers specific for fiactin, Etv4, GAPDH and Shp2. The gel conditions are: 1% agarose gel in IX TBE ran at 100
volts for 45 minutes.
(1) DNA ladder
(2) [3-actin + reverse transcriptase
(3) |3-actin ‘no reverse transcriptase’ control
(4) Etv4 + reverse transcriptase
(5) Etv4 ‘no transcriptase’ control
(6) GAPDH + reverse transcriptase
(7) GAPDH ‘no reverse transcriptase’ control
(8) Shp2 + reverse transcriptase
(9) Shp2 ‘no transcriptase’ control

Page 63 of 85

Figure No. 11 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed with 1 in 5 diluted lOOng/mL of RNA template using se
quence specific reverse primers followed by polymerase chain reaction with primers specific for pactin, Spry 1, GAPDH, and Shp2. The gel conditions are: 1% agarose gel in IX TBE ran at 100
volts for 45 minutes.
(1) DNA ladder
(2) p-actin + reverse transcriptase
(3) P-actin ‘no reverse transcriptase’ control
(4) Spryl + reverse transcriptase
(5) Spryl ‘no transcriptase’ control
(6) GAPDH + reverse transcriptase
(7) GAPDH ‘no reverse transcriptase’ control
(8) Shp2 + reverse transcriptase
(9) Shp2 ‘no transcriptase’ control
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Figure No. 12 Real-Time PCR using SYBR Green
The real-time PCR reaction was performed as two-step reaction. The reverse transcriptase reac
tion was performed with gene-specific reverse primers for Spryl and P-actin using 1 in 5 diluted
100ng/mL RNA. The polymerase chain reaction with cDNA and SYBR green was carried out
subsequently in a separate reaction tube. The amplification plot shows the fluorescence signal
versus the cycle number. The normalized reported (Rn) is the ratio of the fluorescence emission
of the reporter dye to the fluorescence emission of the passive dye. The baseline refers to the ini
tial cycles of the reaction where there is minimal change fluorescence signal. The (ARn) is the
baseline subtracted from the Rn. The cycles represent the cycles as the polymerase chain reaction
progresses. Spryl is represented by the yellow line and P-actin is represented by the green line.
The ‘+ reverse transcriptase’ control for Spryl resulted in a Ct value of 37.07, the ‘no reverse
transcriptase’ 21.89, and the ‘no template’ control resulted in a Ct value of 34.02. The ‘+ reverse
transcriptase’ control for P-actin resulted in a Ct value of 14.5, the ‘no reverse transcriptase’ con
trol, 36.01 and the ’no template’ control 26.87.
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Real-Time qPCR TaqMan Average Ct Values
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Figure No. 13 Average Ct value of RET dependent signaling proteins
Technical replicates were used for the Real-Time qPCR TaqMan reactions as opposed to biologi
cal replicates. Three replicates were used to control for validity of the method. The average and
± standard deviations of the replicates are presented as statistical validation for the replicates test
ed. The bar height indicates the average expression of each gene in response to the three experi
mental conditions: (serum-free) untreated, 4-hr serum treatment and 4-hr GDNF treatment.
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Figure No. 14 The A in Ct Average of RET dependent signaling proteins
The bar height represent the A in Ct Average that is calculated by subtracted the average Ct of
the endogenous control form the average Ct of the target gene. The three bar per gene represent
the experimental conditions, (serum-free) untreated, 4-hr serum treatment and 4-hr GDNF treat
ment, respectively. The top graph represents the A in Ct average for GAPDH. The bottom
graph represent the A in Ct Average for [3-actin.
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Table No. 1 Data Normalized to [3-actin relative to treatment using Livak AACt Method
Relative quantification of gene expression measures the differences in expression levels of a target
between samples. It is the change in expression of a target in a sample relative to the same target
in a reference sample. The table represents the separate real-time qPCR experiments performed
with TaqMan gene expression assays that were normalized to p-actin. The data is presented as
the experimental conditions followed by the averages with ± standard deviations of the three
technical replicates. The data is read as a fold-difference of expression levels. The amplification
efficiency of the assays are listed on the right.
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Figure No. 15 Standard Curve for J3-actin
The amplification efficiency of real-time PCR assays were assessed by standard curves construct
ed with serial dilutions of the 100ng/mL RNA template extracted from SK-N-SH untreated
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to
calculate slope and R 2value. The experimental conditions were tested with 1 in 10 diluted (0.1X)
100ng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes
labeled ‘not assigned’ in the legend.
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Figure No. 16 Standard Curve for Spryl
The amplification efficiency of real-time PCR assays were assessed by standard curves construct
ed with serial dilutions of the 100ng/niL RNA template extracted from SK-N-SH untreated
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to
calculate slope and R 2value. The experimental conditions were tested with 1 in 10 diluted (0.1X)
lOOng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes
labeled ‘not assigned’ in the legend. The 0.0 IX values are not plotted in the curve.

Page 70 of 85

St andarci Curve
»*§
m§
»0

Standard Curve for Shp2

as

I

11«

ti» I

9»« I
«0 ■
»• i
MM

°

MM

I
'

X«
tf » ■3f M
38 $ =

MO
MM
MM

I

"
340
219 "

QuMft
o#*l»«lirwrt|4Iw
p

ito»C
im
u
rri*«;■B Strofi*I»««*«f*t»«j

*»
rt*
*
■
;-*
>
m
^
»

Figure No. 17 Standard Curve for Shp2
The amplification efficiency of real-time PCR assays were assessed by standard curves construct
ed with serial dilutions of the 1OOng/mL RNA template extracted from SK-N-SH untreated
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to
calculate slope and R 2value. The experimental conditions were tested with 1 in 10 diluted (0.1X)
1OOng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes
labeled ‘not assigned’ in the legend.
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Figure No. 18 Standard Curve for Etv4
The amplification efficiency of real-time PCR assays were assessed by standard curves construct
ed with serial dilutions of the 1OOng/mL RNA template extracted from SK-N-SH untreated
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to
calculate slope and R 2value. The experimental conditions were tested with 1 in 10 diluted (0.1X)
100ng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes
labeled ‘not assigned’ in the legend.
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Figure No. 19 Data Normalized to (3-actin relative to treatment using Livak AACt Method
Real-time PCR analysis of the expression levels using predesigned TaqMan gene expression as
says. Data was normalized to ff-actin. The values represent fold changes relative to the untreated
(serum-free) control and are given as the fold difference with ± standard deviations and p values.
The values are presented as relative fold changes with upregulation > 1 and downregulation < 1.
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Table No. 2 Data Normalized to GAPDH relative to treatment using Livak AACt Method
Relative quantification of gene expression measures the differences in expression levels of a target
between samples. It is the change in expression of a target in a sample relative to the same target
in a reference sample. The table represents the separate real-time PCR experiments performed
with TaqMan gene expression assays that were normalized to GAPDH. The data is presented as
the experimental conditions followed by the averages with ± standard deviations of the three
technical replicates. The data is read as a fold-difference of expression levels. The amplification
efficiency of the assays are listed on the right.
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Figure No. 20 Standard Curve for GAPDH
The amplification efficiency of real-time PCR assays were assessed by standard curves construct
ed with serial dilutions of the 1OOng/mL RNA template extracted from SK-N-SH untreated
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to
calculate slope and R 2value. The experimental conditions were tested with 1 in 10 diluted (0. IX)
100ng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes
labeled ‘not assigned’ in the legend.
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Figure No. 21 Standard Curve for Spryl
The amplification efficiency of real-time PCR assays were assessed by standard curves construct
ed with serial dilutions of the 100ng/mL RNA template extracted from SK-N-SH untreated
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to
calculate slope and R 2value. The experimental conditions were tested with 1 in 10 diluted (0.1X)
1OOng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes
labeled ‘not assigned’ in the legend.
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Figure No. 22 Standard Curve for Shp2
The amplification efficiency of real-time PCR assays were assessed by standard curves construct
ed with serial dilutions of the 1OOng/mL RNA template extracted from SK-N-SH untreated
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to
calculate slope and R 2value. The experimental conditions were tested with 1 in 10 diluted (0.1X)
100ng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes
labeled ‘not assigned' in the legend.
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Figure No. 23 Standard Curve for Etv4
The amplification efficiency of real-time PCR assays were assessed by standard curves construct
ed with serial dilutions of the 100ng/mL RNA template extracted from SK-N-SH untreated
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to
calculate slope and R 2value. The experimental conditions were tested with 1 in 10 diluted (0.1X)
1OOng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes
labeled ‘not assigned’ in the legend.
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Data Normalized to GAPDH relative to treatment
using Livak AACt Method
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Figure No. 24 Data Normalized to GAPDH relative to treatment using Livak AACt Method
Real-time PGR analysis of the expression levels using predesigned TaqMan gene expression as
says. Data was normalized to GAPDH. The values represent fold changes relative to the un
treated (serum-free) control and are given as the fold difference with ± standard deviations and p
values. The values are presented as relative fold changes with upregulation > 1 and downregulation < 1.
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